MedImmune has reported that data from a Phase I study demonstrated that Numax appears to have an acceptable safety profile in infants infected with respiratory syncytial virus (RSV). The drug may have the potential to help reduce RSV in the upper-respiratory tracts of children infected with the virus.
MedImmune is developing Numax as a potential improvement to Synagis, which it introduced to the market in 1998.
In preclinical studies, Numax has shown increased potency against RSV when compared to Synagis. Earlier this year, MedImmune presented this information and other data from Phase I and Phase I/II studies at scientific meetings in the U.S. and Curacao that provided evidence that Numax was safe and well-tolerated in high-risk infants.